This is the authors' abstract. We don't add key points for this paper.
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bonilla‐Abadía et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: